salmeterol xinafoate has been researched along with Glycogen Storage Disease Type II in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Everitt, JI; Han, SO; Koeberl, DD; Li, S | 1 |
| Han, SO; Koeberl, DD; Li, S | 1 |
2 other study(ies) available for salmeterol xinafoate and Glycogen Storage Disease Type II
| Article | Year |
|---|---|
Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease.
Topics: Animals; Dependovirus; Disease Models, Animal; Enzyme Activation; Gene Expression; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Glycogen Storage Disease Type II; Mice; Mice, Knockout; Muscle, Skeletal; Receptor, IGF Type 2; Salmeterol Xinafoate; Transduction, Genetic | 2019 |
Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
Topics: alpha-Glucosidases; Animals; Clenbuterol; Dehydroepiandrosterone; Dependovirus; Disease Models, Animal; Enzyme Replacement Therapy; Genetic Therapy; Genetic Vectors; Glycogen; Glycogen Storage Disease Type II; Humans; Mice; Mice, Knockout; Myocardium; Salmeterol Xinafoate | 2016 |